Analyst Ratings for Kinnate Biopharma (KNTE) [Neutrals]
KNTE Rating Summary
KNTE Price Target Summary
- Highest: $4.00 (Piper Sandler)
- Lowest: $2.00 (Wedbush)
- Average: $2.65
* Over Last 12-Mos
Overall Rating:
NEUTRAL
Rating Trend:
Avg. $ Target:
$2.65 (-0.1%)
* Over Last 12-Mos
Rating Score: 3.8 / 10
Percentile Rank: 36%
Avg. $ Target:
$2.65 (-0.1%)
* Over Last 12-Mos
Rating Score: 3.8 / 10
Percentile Rank: 36%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 2/16/2024 | William Blair | Tim Lugo | Downgrade | Market Perform (Outperform) |
N/A (N/A) |
2.27 (2.65) |
16.74% | Details |
| 9/19/2023 | Wedbush | David Nierengarten | Downgrade | Neutral (Outperform) |
2.00 (14.00) |
1.70 (2.65) |
55.88% | Details |
 |
||||||||
|
||||||||
|
||||||||
